Grifols, S.A.

Equities

GRF

ES0171996087

Pharmaceuticals

Market Closed - BME 16:42:40 23/07/2024 BST 5-day change 1st Jan Change
9.014 EUR -1.40% Intraday chart for Grifols, S.A. -1.42% -41.68%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
European Equities Traded in the US as American Depositary Receipts Open Week Sharply Higher in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading MT
Grifols, S.A. Announces Board and Committee Appointments CI
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading MT
Moody's Removes Rating of Spanish Pharmaceutical Grifols MT
Grifols, S.A. Announces Board Resignations and Establishment of Transaction Committee CI
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday MT
Grifols Shares Surge on Take-Private Talks MT
Europe's STOXX 600 dips ahead of Powell testimony; Indivior sinks RE
ADRs Slump; SYLA Technologies Declines 35% DJ
European Equities Close Mixed in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading MT
GRIFOLS : A strategic move or a ploy to arrest further shareholder wealth erosion? Alphavalue
That's not so bad, is it? Our Logo
Top Premarket Gainers MT
Grifols Family Holders, Brookfield to Evaluate Possible Joint Takeover Bid CI
TSX futures muted as commodities decline amid rate cut hopes RE
Trending : Grifols Founding Family, Brookfield Eye Takeover Bid for Spanish Drugmaker DJ
Grifols Receives Takeover Interest from Founding Family, Brookfield; Shares Suspended MT
Grifols Faces Delisting Bid From Founding Family and Brookfield DJ
Grifols Receives Takeover Interest from Founding Family, Brookfield; Shares Suspended MT
Chart Grifols, S.A.
More charts
Logo Grifols, S.A.
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.1%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).
Employees
23,000
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
9.014EUR
Average target price
17.64EUR
Spread / Average Target
+95.66%
Consensus
  1. Stock Market
  2. Equities
  3. GRF Stock
  4. News Grifols, S.A.
  5. European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading